39
37. National Institute for Clinical Excellence. Guide to the Methods of Technology
Appraisal. 2004 [Acessado em 21/05/2007]; Disponível em:
http://www.nice.org.uk/pdf/TAP_Methods.pdf
38. O'Brien BJ, Connolly SJ, Goeree R, Blackhouse G, Willan A, Yee R, et al. Cost-
effectiveness of the implantable cardioverter-defibrillator: results from the Canadian
Implantable Defibrillator Study (CIDS). Circulation. 2001 Mar 13;103(10):1416-21.
39. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The
effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S.
Carvedilol Heart Failure Study Group. N Engl J Med. 1996 May 23;334(21):1349-55.
40. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of
carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001 May
31;344(22):1651-8.
41. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, et
al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with
moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation
of Carvedilol on Symptoms and Exercise. Circulation. 1996 Dec 1;94(11):2793-9.
42. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a
selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial
infarction. N Engl J Med. 2003 Apr 3;348(14):1309-21.
43. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of
spironolactone on morbidity and mortality in patients with severe heart failure. Randomized
Aldactone Evaluation Study Investigators. N Engl J Med. 1999 Sep 2;341(10):709-17.
44. Sanders G, Hlatky M, Owens D. Cost-Effectiveness of Implantable Cardioverter-
Defibrillators in a MADIT-II Population. TEC Assessment. 2004;19(3):1-26.